SOLTI-1910: Predicting olaparib sensitivity in patients with unresectable locally advanced/metastatic HER2-negative breast cancer with BRCA1/2, PALB2, RAD51C/D mutations or HRD by the RAD51 test: RADIOLA trial

Balmana, J.Pascual, T.Llop-Guevara, A.Tolosa, P.Blancas Lopez-Barajas, I.Perez Lopez, M. E.Adamo, B.Teruel-Garcia, I.Ponce, J.Gonzalez-Cordero, M.Vinas Villaro, G.Lema Roso, L.Salvador Bofill, F. J.Martinez, M. T. M.Guerrero, A. N. E.Prat, A.Serra Elizalde, V.2023-05-032023-05-032022-05-050923-7534http://hdl.handle.net/10668/21898enSOLTI-1910: Predicting olaparib sensitivity in patients with unresectable locally advanced/metastatic HER2-negative breast cancer with BRCA1/2, PALB2, RAD51C/D mutations or HRD by the RAD51 test: RADIOLA trialconference outputopen access10.1016/j.annonc.2022.03.0721569-8041http://www.annalsofoncology.org/article/S0923753422004513/pdf792494100060